Skip Navigation

Cardiovascular Research 2001 49(1):152-160; doi:10.1016/S0008-6363(00)00238-8
© 2001 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stanke-Labesque, F.
Right arrow Articles by Bessard, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanke-Labesque, F.
Right arrow Articles by Bessard, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats

Françoise Stanke-Labesque*, Philippe Devillier1, Sophie Veitl, Françoise Caron, Jean-Luc Cracowski and Germain Bessard

Laboratory of Pharmacology, University of Medicine, LSCPA EA2937 F-38706, La Tronche Cedex, France

* Corresponding author. Tel.: +33-4-7663-7159; fax: +33-4-7651-8667 Francoise.Stanke{at}ujf-grenoble.fr

Objective: Non specific lipoxygenase inhibitors have been reported to reduce the in vitro constrictor response and the in vivo pressor effect of angiotensin II in rats. The aim of this study was to assess the role of cysteinyl leukotrienes, in the vascular response to angiotensin II in spontaneously hypertensive rats (SHR). Methods: Rings of thoracic aorta from SHR and normotensive Wistar–Kyoto rats (WKY) were compared in terms of contractile responses and release of cysteinyl leukotrienes in response to angiotensin II. Results: Pretreatment with the specific 5-lipoxygenase inhibitor AA861 10 µM reduced the efficacy of angiotensin II in intact and endothelium-denuded aorta from SHR (% inhibition vs. control: 65±12.6% with endothelium (n = 6), P<0.05; 43±7.2% without endothelium (n = 6), P<0.05) but not in aorta from WKY. In addition, in aorta from SHR, the CysLT1 receptor antagonist MK571 1 µM reduced by 55±6.1% (n = 6, P<0.05) the contractile effects of angiotensin II in rings with endothelium but not in endothelium-denuded rings. Angiotensin II induced a 8.6±2.1-fold increase in cysteinyl leukotriene production in aorta rings from SHR with endothelium which was prevented by the AT1 receptor antagonist losartan 1 µM but not by the AT2 receptor antagonist PD123319 0.1 µM. In aorta rings from WKY, cysteinyl leukotriene production remained unchanged after exposition to angiotensin II. The cysteinyl leukotrienes (up to 0.1 µM) induced contractions in aorta rings from SHR but not from WKY. Conclusions: These data suggest that cysteinyl leukotrienes, acting at least in part on endothelial CysLT1 receptors, are involved in the contractile response to angiotensin II in isolated aorta from SHR but not from WKY.

KEYWORDS Angiotensin; Arteries; Contractile function; Hypertension; Lipid metabolism; Receptors

1 Present address: Laboratory of Pharmacology, IFR 53, EA2070, Faculty of Medicine, F-51092 Reims, France.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.